PropertyValue
?:abstract
  • We compared severe acute respiratory syndrome–related coronavirus-2 seroprevalence estimated from commercial laboratory residual sera and a community household survey in metropolitan Atlanta during April-May 2020 and found these two estimates to be similar (4.94% versus 3.18%). Compared with more representative surveys, commercial sera can provide an approximate measure of seroprevalence.
is ?:annotates of
?:creator
?:doi
  • 10.1093/cid/ciaa1804
?:doi
?:journal
  • Clin_Infect_Dis
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/8f2cef46e47bf5bccc0fa487680a78aae13f1e8e.json
?:pmcid
?:pmid
?:pmid
  • 33300579.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Comparison of Estimated SARS-CoV-2 Seroprevalence through Commercial Laboratory Residual Sera Testing and a Community Survey
?:type
?:year
  • 2020-12-10

Metadata

Anon_0  
expand all